133 related articles for article (PubMed ID: 17537139)
1. Does cost-effectiveness play a role in clinical trials?
Steele T; Pawaskar M; Balkrishnan R; Fleischer A; Feldman SR
Dermatol Ther; 2007; 20(2):110-9. PubMed ID: 17537139
[TBL] [Abstract][Full Text] [Related]
2. Economic outcomes and contemporary pharmacy practice.
Reeder CE
Am Pharm; 1993 Dec; NS33(12 Suppl):S3-6. PubMed ID: 8109541
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
Weintraub WS
J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
[TBL] [Abstract][Full Text] [Related]
4. Design and analysis issues for economic analysis alongside clinical trials.
Marshall DA; Hux M
Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomics.
Ahuja J; Gupta M; Gupta AK; Kohli K
Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
[TBL] [Abstract][Full Text] [Related]
6. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
7. [Economic aspects of diagnosis, treatment and rehabilitation of patients with malignant skin neoplasms].
Stranadko EF; Aleksandrova LA; Khadzhiev MA
Sov Med; 1990; (9):39-40. PubMed ID: 2148438
[No Abstract] [Full Text] [Related]
8. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study.
Schmitt J; Meurer M; Klon M; Frick KD
Br J Dermatol; 2008 Feb; 158(2):351-9. PubMed ID: 18070214
[TBL] [Abstract][Full Text] [Related]
9. Potential barriers to adherence in pediatric dermatology.
Ellis RM; Koch LH; McGuire E; Williams JV
Pediatr Dermatol; 2011; 28(3):242-4. PubMed ID: 21615470
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and completeness of clinical trial registrations in psoriasis and atopic dermatitis.
Quain RD; Katz KA
Br J Dermatol; 2007 Jan; 156(1):106-10. PubMed ID: 17199575
[TBL] [Abstract][Full Text] [Related]
11. Economic considerations in psoriasis management.
Radtke MA; Augustin M
Clin Dermatol; 2008; 26(5):424-31. PubMed ID: 18755360
[TBL] [Abstract][Full Text] [Related]
12. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
15. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.
Carrington M; Stewart S
Int J Cardiol; 2008 Jun; 127(1):51-6. PubMed ID: 17586072
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of psoriasis therapy with etanercept in Germany.
Heinen-Kammerer T; Daniel D; Stratmann L; Rychlik R; Boehncke WH
J Dtsch Dermatol Ges; 2007 Sep; 5(9):762-8. PubMed ID: 17760896
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of the US Environmental Protection Agency's SunWise program: sun protection education for young children.
Kyle JW; Hammitt JK; Lim HW; Geller AC; Hall-Jordan LH; Maibach EW; De Fabo EC; Wagner MC
Pediatrics; 2008 May; 121(5):e1074-84. PubMed ID: 18450850
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of group psychotherapy for depression in Uganda.
Siskind D; Baingana F; Kim J
J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
[TBL] [Abstract][Full Text] [Related]
20. Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluations.
Maclure M; Carleton B; Schneeweiss S
Med Care; 2007 Oct; 45(10 Supl 2):S44-9. PubMed ID: 17909382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
